# Direct Pulp Capping Agent on Human Pulp Tissue

> **NCT06435065** · PHASE4 · RECRUITING · sponsor: **DR SURINDER SACHDEVA** · enrollment: 40 (estimated)

## Conditions studied

- Reversible Pulpitis

## Interventions

- **DRUG:** Biodentine
- **DRUG:** Mineral Tri-Oxide Aggregate
- **DRUG:** THERACAL LC
- **DRUG:** TRISTRONTIUM ALUMINATE

## Key facts

- **NCT ID:** NCT06435065
- **Lead sponsor:** DR SURINDER SACHDEVA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2024-06
- **Final completion:** 2024-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435065, "Direct Pulp Capping Agent on Human Pulp Tissue". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06435065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*